DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Alirocumab
Alirocumab
125559Orig1s000
Lipid-Lowering Therapy and Low-Density Lipoprotein Cholesterol
Background A. Rodríguez-Alarcón1, C. López1, E. González-Colominas1
Intervention to Improve LDL Receptor Function Emerging Therapies
PCSK9 Inhibitor Non-Response in a Patient with Preserved LDL Receptor
Praluent® (Alirocumab)
Praluent, INN-Alirocumab
PRALUENT® (Alirocumab) Injection, for Subcutaneous Use ————————— DOSAGE FORMS and STRENGTHS ————————— Initial U.S
Effect of Alirocumab on Individuals with Type 2 Diabetes, High
PRALUENT (Alirocumab) RATIONALE for INCLUSION in PA PROGRAM
Bempedoic Acid
Bempedoic Acid, Bempedoic Acid/Ezetimibe (Nexletol™, Nexlizet™) EOCCO POLICY Policy Type: PA/SP Pharmacy Coverage Policy: EOCCO182
PRALUENT (Alirocumab)
Enhancing the Value of PCSK9 Monoclonal Antibodies by Identifying Patients Most Likely to Benefit
Anatomical Classification Guidelines V2020 EPHMRA ANATOMICAL
Alirocumab (Praluent) Reference Number: CP.PHAR.124 Effective Date: 10.15 Last Review Date: 08.19 Line of Business: Commercial, Medicaid Revision Log
Efficacy of Adding Alirocumab to Rosuvastatin Versus Other Treatment Strategies
And BEMPEDOIC ACID-EZETIMIBE Tablets
Top View
Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs
PCSK9 Inhibitors
Alirocumab in Combination with Statins for CVD Risk Reduction: an Evidential Review
Alirocumab (Praluent®)
A Review of the Efficacy and Tolerability of Bempedoic Acid In
Bococizumab for Primary Hyperlipidaemia and Mixed Dyslipidaemia – Adjunctive to Statin Therapy And/Or Diet
Alirocumab (Praluent) Reference Number: ERX.SPA.168 Effective Date: 01.11.17 Last Review Date: 08.18 Revision Log
PRALUENT® (Alirocumab) Injection, for Subcutaneous Use LDL Apheresis
Lipotropics, Other
CLINICAL REVIEW(S) Clinical Review Ovidiu A
Alirocumab) Injection, for Subcutaneous Use Initial U.S
Praluent, INN-Alirocumab
Introduction Bile Acid Sequestrants
Genetics of Dyslipidemia
Praluent, INN-Alirocumab
The Importance of Lipoprotein Lipase Regulationin Atherosclerosis
For Review at September 24, 2020, Meeting: Antihyperlipidemics
Anatomical Classification Guidelines V2018 EPHMRA ANATOMICAL